**Study includes country-level data for 204 countries and territories worldwide. A link to summary tables for rates in selected countries as well as country-level data is included at the end of the press release**
- Most comprehensive global analysis to date estimates that overweight and obesity rates in adults (aged 25 or older) and children and adolescents (aged 5-24 years) more than doubled over the past three decades (1990-2021), affecting 2.11 billion adults and 493 million young people worldwide in 2021.
- Weight gain varies widely across the globe with more than half of the world’s adults with overweight or obesity in 2021 living in just eight countries—China (402 million), India (180 million), the USA (172 million), Brazil (88 million), Russia (71 million), Mexico (58 million), Indonesia (52 million), and Egypt (41 million).
- Without urgent policy reform and action, around 60% of adults (3.8 billion) and a third (31%) of all children and adolescents (746 million) are forecast to be living with either overweight or obesity by 2050.
- Globally, the predicted surge in child and adolescent obesity is expected to outpace the increase in overweight, with substantial increases expected immediately (2022-2030). Children and young adolescents, especially males, are expected to fare worse—with levels of obesity (16.5%) overtaking overweight (12.9%) in males aged 5-14 years by 2050.
- By 2050, one in three young people with obesity (130 million) are forecast to be living in just two regions—north Africa and the Middle East and Latin America and the Caribbean—with deleterious health, economic, and societal consequences.
- Additionally, nearly a quarter of the world’s adult population with obesity in 2050 are predicted to be aged 65 or older, intensifying the strain on already overburdened health-care systems and wreaking havoc on health services in low-resource countries.
- The authors say the findings underscore the imperative for immediate action to prevent an unprecedented global epidemic of overweight and obesity.
Without urgent policy reform and action, over half the world’s adult population (3.8 billion) and a third of all children and adolescents (746 million) are forecast to be living with overweight or obesity by 2050—posing an unparalleled threat of premature disease and death at local, national, and global levels, according to a major new analysis from the Global Burden of Disease Study BMI Collaborators, published in The Lancet.
Massive global failures in the response to the growing obesity crisis over the past three decades contributed to a startling increase in the number of adults (aged 25 and older) and children and adolescents (aged 5-24 years) with overweight and obesity worldwide, rising from 731 million and 198 million respectively in 1990, to 2.11 billion and 493 million in 2021.
The study predicts a substantial (121%) rise in obesity among young people globally, with the total number of children and adolescents with obesity predicted to reach 360 million by 2050 (an additional 186 million from 2021). The substantial increases in obesity forecast between 2022 and 2030, underscore the urgent need for action.
“The unprecedented global epidemic of overweight and obesity is a profound tragedy and a monumental societal failure,” said lead author Professor Emmanuela Gakidou from the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA. “Governments and the public health community can use our country-specific estimates on the stage, timing, and speed of current and forecasted transitions in weight to identify priority populations experiencing the greatest burdens of obesity who require immediate intervention and treatment, and those that remain predominantly overweight and should be primarily targeted with prevention strategies.”
The new analysis estimated the prevalence of overweight and obesity for children and young adolescents (aged 5-14 years), older adolescents (aged 15-24 years), and adults (aged 25 and older) in 204 countries and territories from 1990 to 2021 with forecasts from 2022 to 2050 (assuming continuation of past trends and patterns as well as policies and interventions) using up to 1,350 unique data sources, including all major multi-country and national survey data. Adjustments were made to correct for self-reporting bias.
The study used body mass index (BMI) for adults—widely used to track current global trends. For individuals older than 18 years, overweight was defined as having a BMI of 25 kg/m² to less than 30 kg/m² and obesity was defined as a BMI of 30 kg/m² or higher. For individuals younger than 18 years definitions were based on International Obesity Task Force criteria [1].
60% of adults predicted to have overweight or obesity by 2050
Almost half of the global adult population (1 billion males and 1.11 billion females aged 25 or older) were estimated to be living with overweight or obesity in 2021. The prevalence of obesity more than doubled worldwide between 1990 and 2021 in both adult men (from 5.8% to 14.8%) and women (10.2% to 20.8%).
Especially high levels have already been reached in Oceania and north Africa and the Middle East, with over 62% of adult males in Nauru, Cook Islands, and American Samoa, and over 71% of adult females in Tonga and Nauru living with obesity in 2021. Among high-income countries, the USA had the highest rates of obesity, with around 42% of males and 46% of females affected by obesity in 2021.
Continuation of these trends would see global rates of overweight and obesity among adults rise from an estimated 43.4% in 2021 to around 57.4% for men in 2050, and from 46.7% to 60.3% for women, with the largest increases projected in Asia and sub-Saharan Africa, driven by growing populations. This would mean an estimated 1.69 billion additional adults living with overweight or obesity by 2050 (raising the total to 3.8 billion, of whom 1.95 billion will have obesity).
While the largest number of adults with overweight and obesity are still expected in China (627 million), India (450 million) and the USA (214 million) in 2050, the number in sub-Saharan Africa is forecast to rise by over 250% to 522 million, driven by population growth (see appendix 2 figure S8).
Worldwide, Nigeria stands out for its predicted rise in adults with overweight and obesity, with the number projected to more than triple from 36.6 million in 2021 to 141 million in 2050—making it the country with the fourth-largest population of adults with overweight and obesity (see appendix 2 tables S6 and S7, figure S8)
Around one in three adults worldwide are expected to be affected by obesity in 2050—of whom around a quarter are forecast to be 65 years and older—with the highest levels in the United Arab Emirates and Nauru (more than 80% of males expected to have obesity in 2050); and in Tonga and Egypt (at least 87% of females; see appendix figures S6 and S7).
“Obesity rates are skyrocketing across sub-Saharan Africa, with 522 million adults and more than 200 million young people expected to be living with overweight or obesity by 2050,” said co-author Awoke Temesgen, clinical Associate Professor at IHME. “This has added a double burden to the already overstretched healthcare systems that are ill-equipped to handle the extraordinary rise in obesity-related disease. Action is urgently needed to implement preventative initiatives such as polices on marketing of unhealthy foods and planning to include facilities for exercise and playing fields in schools.”
Importantly, the authors note that more recent generations are gaining weight faster than previous ones and obesity is occurring earlier, increasing the risk of complications such as type 2 diabetes, high blood pressure, cardiovascular diseases, and multiple cancers occurring at younger ages. For example, in high-income countries, approximately 7% of men born in the 1960s were living with obesity at the age of 25, but this increased to around 16% for men born in the 1990s, and is forecast to reach 25% for men born in 2015.
One in three young people predicted to have overweight or obesity in 2050
The new analysis estimates that the global prevalence of overweight and obesity in young people rose substantially between 1990 and 2021, doubling in both children and younger adolescents (from 8.8% to 18.1%) and older adolescents (from 9.9% to 20.3%), affecting 493 million young people in 2021. Similarly, obesity rates in children and adolescents tripled from 2% to nearly 7%, with 174 million young people living with obesity in 2021.
The study predicts that overweight during childhood and adolescence will stabilise between 2021 and 2050 as larger numbers in all world regions shift to obesity, with substantial increases expected immediately between 2022 and 2030, with increases continuing beyond 2031 to 2050. Globally, more 5–14-year-old males are forecast to be living with obesity compared to overweight by 2050 (16.5% vs 12.9%), whereas in females (5-24 years) and older males (15-24 years), overweight is still expected to remain more prevalent than obesity.
The most rapid accelerations in obesity are forecast in north Africa and the Middle East and Latin America and the Caribbean, where one-third of all the world’s children and adolescents with obesity (130 million) are expected to live in 2050. The transition to obesity predominance (versus overweight) is also expected to be overwhelming for several Oceanic countries (e.g., Cook Islands, Nauru, Tonga) where levels of obesity are expected to reach 60-70% by 2050, as well as for heavily populated countries such as Nigeria (18.1 million), India (26.4 million), Brazil (17.8 million), China (35.2 million), and the USA (22.1 million) where the numbers of young people with obesity are forecast to soar.
“But if we act now, preventing a complete transition to global obesity for children and adolescents is still possible,” said co-lead author Dr Jessica Kerr from Murdoch Children’s Research Institute in Australia. “Our estimates identify children and adolescents in much of Europe and south Asia living with overweight who should be targeted with obesity prevention strategies. We have also identified large populations, particularly adolescent girls, in North America, Australasia, Oceania, north Africa and the Middle East, and Latin America that are expected to tip over to obesity predominance and require urgent, multifaceted intervention and treatment. This is essential to avoid intergenerational transmission of obesity and to prevent a wave of serious health conditions and dire financial and societal costs for future generations.”
A new roadmap for obesity prevention
The authors stress that 5-year action plans (2025-2030) are urgently required to curb the rise in obesity and help inform new goals and targets for the post-2030 Sustainable Development Goal-era. The authors call for more concerted efforts to deliver comprehensive, transdisciplinary interventions tailored to each county’s unique socio-demographic, economic, environmental, and commercial situation.
“Preventing obesity must be at the forefront of policies in low- and middle-income countries,” said Dr Kerr. “Policy action in these regions must balance the challenges of overnutrition with undernutrition and stunting, with interventions ranging from support for nutritional diets and regulating ultra-processed foods to promoting maternal and child health programmes that encourage pregnant women to follow a healthy diet and breastfeed. This is no time for business as usual. Many countries only have a short window of opportunity to stop much greater numbers shifting from overweight to obesity.”
She added, “Ultimately, as global obesity rates continue to soar, much stronger political commitment is needed to transform diets within sustainable global food systems and to support comprehensive strategies that improve people’s nutrition, physical activity and living environments, whether it's too much processed food or not enough parks.”
The authors note some important limitations, including that while the study uses the best available data, predictions are constrained by the quantity and quality of past data as well as systemic biases from self-reported data, which are likely to remain despite attempts to correct for bias. They also note that the definition of overweight and obesity is based on BMI, which does not account for variations in body structure across ethnic groups and subpopulations. Finally, the study did not consider the potential impact of interventions, such as the scale-up of GLP-1 anti-obesity medications, that could alter the longer-term forecasting trends of overweight and obesity.
Writing in a linked Comment, Thorkild I A Sørensen of the University of Copenhagen, Denmark (who was not involved with the study) said: “The scale of the epidemic is such that solutions will have to be public health interventions, also considering the profound macro-level and micro-level heterogeneity of the development of the epidemic. In particular, the consistent and unexplained tendency towards a higher prevalence among socially deprived groups enhances the challenges. The most pressing question concerns which interventions will be both feasible and effective. Although the components of the global environment, presumed to be driving the epidemic, in principle should be reversible, rolling them back to before the emergence or acceleration of the obesity epidemic is clearly unrealistic…Further understanding of the causes and mechanisms of obesity development could pave the way to improved lasting prevention.”
NOTES TO EDITORS
The study was funded by the Bill & Melinda Gates Foundation. It was conducted by the GBD 2021 Adolescent and Adult BMI Collaborators.
Quotes from Authors cannot be found in the text of the Article, but have been supplied for the press release. The Comment quote is taken directly from the linked Comment.
[1] Extended international (IOTF) body mass index cut‐offs for thinness, overweight and obesity - Cole - 2012 - Pediatric Obesity - Wiley Online Library
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
F YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS:
Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with
forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00397-6/fulltext
Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00355-1/fulltext
Journal
The Lancet
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
Article Publication Date
3-Mar-2025
COI Statement
Q E S Adnani reports grants or contracts from Online Library Data Research funds from Universitas Padjadjaran, Bandung, Indonesia, under contract number 2152/UN6.3.1/PT.00/2024 and Acceleration to Associate Professor Grant from Universitas Padjadjaran, Bandung, Indonesia under contract number 1592/UN6.3.1/PT.00/2024, outside the submitted work. S Afzal reports support for their support in the present manuscript from King Edward Medical University; payment or honoraria for lectures, presentations, or educational events from King Edward Medical University and collaborative partners including University of Johns Hopkins, University of California, University of Massachusetts, KEMCAANA, KEMCA_UK international scientific conferences, webinars and meetings; support for attending meetings and/or travel from King Edward Medical University; participation on a data safety monitoring board or advisory board with National Bioethics Committee Pakistan, King Edward Medical University Ethical Review Board, Ethical Review Board Fatima Jinnah Medical University and Sir Ganga Ram Hospital, Member Technical Working Group on Infectious Diseases to formulate guidelines; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid) Pakistan Association of Medical Editors, Fellow of Faculty of Public Health Royal Colleges UK (FFPH), Society of Prevention, Advocacy And Research, King Edward Medical University (SPARK), Member Pakistan Society of Infectious Diseases; other financial or non-financial interests through serving as Dean of Public Health and Preventive Medicine King Edward Medical University, Chief Editor Annals of King Edward Medical University since 2014, Director Quality Enhancement Cell King Edward Medical University, Fellow of Faculty of Public Health United Kingdom. Advisory Board Member and Chair Scientific Session, KEMCA-UK, Chairperson International Scientific Conference, KEMCAANA, At National level, Member Research and Publications Higher Education Commission, HEC Pakistan, Member Research and Journals Committee Pakistan Medical and Dental Council, Pakistan Member National Bioethics Committee, Pakistan At Punjab Level, Member Corona Experts Advisory Group. Member Technical Working Group on Infectious Diseases to formulate guidelines Member Dengue Experts Advisory Group Chair, Punjab Residency Program Research Committee; all outside the submitted work. S M Alif reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Victoria University Online; support for attending meetings and/or travel from University of Melbourne; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), from Thoracic Society of Australia and New Zealand; all outside the submitted work. R Ancuceanu reports Consulting fees from AbbVie and Merck Romania; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Laropharm, Reckitt, and Merck Romania; support for attending meetings and/or travel from Merck Romania and Reckitt; all outside the submitted work. J Arnlov reports Payment or honoraria for lectures from AstraZeneca and Boehringer Ingelheim; participation on a Advisory Board with AstraZeneca, Astella, outside the submitted work. O C Baltatu reports support for their participation in the current manuscript from Alfaisal University, Anima Institute (AI) Research Professor Fellowship, and National Council for Scientific and Technological Development Fellowship (CNPq, 304224/2022-7); leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), from VividiWise Analytics, and Sao Jose dos Campos Tech Park, outside the submitted work. L Belo reports other financial or non-financial support from FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB, outside the submitted work. S Bhaskar reports grants or contacts from Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) through Grant-in-Aid for Scientific Research (KAKENHI) (23KF0126) and JSPS and the Australian Academy of Science through JSPS International Fellowship (P23712); leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), with the Rotary District 9675, Sydney, Australia, Global Health & Migration Hub Community, Global Health Hub Germany, Berlin, Germany, PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, Journal of Aging Research & BMC Medical Research Methodology, College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada, World Headache Society, Bengaluru, India, Cariplo Foundation, Milan, Italy, National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita, Osaka, Japan, and Cardiff University Biobank, Cardiff, UK; all outside the submitted work. E J Boyko reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Korean Diabetes Association, International Society for the Diabetic Foot, Diabetes Association of the R.O.C. (Taiwan), American Diabetes Association; support for attending meetings and/or travel from Korean Diabetes Association, Diabetes Association of the R.O.C. (Taiwan), International Society for the Diabetic Foot; all outside the submitted work. M Carvalho reports other financial or non-financial support from LAQV/REQUIMTE, University of Porto, Porto, Portugal, and FCT/MCTES under the scope of the project UIDP/50006/2020 (DOI 10.54499/UIDP/50006/2020). N Conrad reports grants or contracts from Research Foundation Flanders (grant number 12ZU922N) through payments to their institute, all outside the submitted work. D Flood reports grants or contracts from NHLBI (award number K23HL161271); consulting fees from serving as a diabetes consultant for the World Health Organization in 2023-2024; all outside the submitted work. A A Fomenkov reports support for their participation in the present manuscript from the Ministry of Science and Higher Educa-tion of the Russian Federation (themes no. 122042600086-7). R C Franklin reports Support for attending meetings and/or travel from ACTM – Annual Conference 2022-2024; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), from President of Australasian College of Tropical Medicine, outside the submitted work. A Guha reports grants or contracts with the Department of Defense from American Heart Association; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), with ZERO Cancer health disparities advisory group; outside the submitted work. A Hassan reports Consulting fees from Novartis, Sanofi Genzyme, Biologix, Merck, Hikma Pharma, Janssen, Inspire Pharma, Future Pharma, Elixir pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Allergan, Merck, Biologix, Janssen, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Al Andalus, Chemipharm, Lundbeck, Inspire Pharma, Future Pharma and Habib Scientific Office, and Everpharma; support for attending meetings and/or travel from Novartis, Allergan, Merck, Biologix, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Chemipharm, and Al Andalus and Clavita pharm; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), as Vice president of MENA headache society, Board member of Multiple Sclerosis chapter of the Egyptian Society of Neurology, Board member of headache chapter of the Egyptian Society of Neurology, member of committee of Education of the international Headache Society (IHS), membership committee of IHS, and regional committee of HIS; all outside the submitted work. A M Hopkins reports support for their participation in the manuscript from National Health and Medical Research Council (Australia); grants or contacts from Tour de Cure, The Hospital Research Foundation, and Grant funding from Boehringer Ingelheim, outside the submitted work. C Hu reports support for their participation in the present manuscript from the National Social Science Fund of China (grant number: 24CSH106).I Ilic reports support for their participation in the present manuscript from the Ministry of Education, Science and Technological Development, Republic of Serbia (project No 175042, 2011-2023).M Ilic reports support for their participation in the present manuscript from the Ministry of Technological Development and Innovation of the Republic of Serbia (no. 451-03-47/2023-01/200111). R M Islam is Associate Editor of Climacteric, the official journal of the International Menopause Society (IMS), and a member of the IMS Publication Steering Committee; these roles are unrelated to the content of this submission. N E Ismail reports Leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, Council Member and The Bursar, Malaysian Academy of Pharmacy (MAP), Malaysia, and the Committee Member, Malaysian Pharmacists Society (MPS) Education Chapter Committee, Malaysia, outside the submitted work. J J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from NOVARTIS, ADAMED, and AMGEN; outside the submitted work. S K Kamarajah reports support for their participation in the current manuscript from NIHR Doctoral Fellowship scheme (NIHR300175). The funders had no role in study design or writing of this report. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the UK Department of Health and Social Care. M Kivamaki reports grants or contracts Wellcome Trust, UK (221854/Z/20/Z), National Institute on Aging (NIH), US (R01AG056477), Medical Research Council, UK (MR/R024227/1, MR/ Y014154/1), Academy of Finland (350426) through grants to their institutions, outside the submitted work. K Krishan reports other nonfinancial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. B Lacey reports grants or contracts from Support from UK Biobank, funded largely by the UK Medical Research Council and Wellcome through payments to their institutions, outside the submitted work. M Lee reports support for their participation in the current manuscript from the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2023S1A3A2A05095298). M-C Li reports support for their participation in the current manuscript from National Science and Technology Council, Taiwan (NSTC 113-2314-B-003-002; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), as Technical Editor, Journal of the American Heart Association, outside the submitted work. D Lindholm reports stock or stock options and other financial interests in AstraZeneca as a former employee, outside the submitted work. S Liu reports grants or contracts from NIH R01ES031391; R01DK125403; R01HL156518; R01HL164485l R01ES034014; U01CA259208; R01HL164485, Royalties or licenses from Uptodate.com; consulting fees from American Society for Nutrition, Fred Hutchinson Cancer Research Center, Guangdong Provincial Hospital, Novo Nordisk, Research Foundation of State University of New York, and Twinhealth.com; support for attending meetings and/or travel from the American Heart Association, Chinese Nutrition Society, European Diabetes and Nutrition Study Group, and American Society of Nutrition; participation on a data safety monitoring board or advisory board with The Select Trial sponsored by Novo Nordisk; all outside the submitted work. S Lorkowski reports grants or contacts from dsmfirmenich (formerly DSM Nutritional Products) through payments to their institution; consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AMARIN Germany, Amedes Holding, AMGEN, Berlin- Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, Swedish Orphan Biovitrum (SOBI), and SYNLAB Holding Deutschland; support for attending meetings and/or travel from AMGEN; participation on a data safety monitoring board or advisory board with AMGEN, Daiichi Sankyo Deutschland, Novartis Pharma, and Sanofi-Aventis; all outside the submitted work. E Lytvyak reports grants or contracts from College of Physicians and Surgeons of Alberta, Government of Alberta, and Advanz Pharma; other financial or non-financial interests in University of Alberta and Alberta Health Services; all outside the submitted work. H R Marateb reports grants or contracts from The Beatriu de Pinos post-doctoral programme from Agency for Management of University and Research Grants, Government of Catalonia program (#2020 BP 00261) through payments to their institution, and from Agency for Management of University and Re-search Grants, Knowledge Industry Grants for 2024. Modality A. LLAVOR (2024 LLAV 00083), outside the submitted work. S A Meo reports grants or contracts from Researchers Supporting Project, King Saud University, Riyadh, Saudi Arabia (RSP-2025 R47), outside the submitted work. S Nomura reports support for their participation in the current manuscript from Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663), and Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8). B Oancea reports grants or contracts from the MRID, project PNRR-I8 no 842027778., contract no 760096, outside the submitted work. A Ortiz reports grants or contracts Sanofi and through the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes; consulting fees, speaker fees or travel support from Advicciene, Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, GSK, Boehringer- Ingelheim, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Idorsia, Chiesi, Otsuka, Novo-Nordisk and Vifor Fresenius Medical Care Renal Pharma; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, with council ERA. SOMANE; all outside the submitted work. S K Panda reports support for their participation in the current manuscript from Siksha ‘O’ Anusandhan (Deemed to be University) through their salary; grants or contracts from DST-GOVT. OF ODISHA (Letter No. 3444/ST); leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid) as associate editor at Heliyon; outside the submitted work. R Passera reports Participation on a data safety monitoring board or advisory board as Member of the Data Safety Monitoring Board of the clinical trial “Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients” - FIL, Fondazione Italiana Linfomi, Alessandria; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), as Member of the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (F), and as a past member 2020–2023 (biostatistician) of the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC; all outside the submitted work. S Rege reports Leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), as Operational Lead – International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Medication Adherence and Persistence (MAP) Special Interest Group (SIG), Review Editor – Editorial Board of Pharmacoepidemiology section within Frontiers in Pharmacology , and Academic Editor – PLOS ONE Editorial Board; outside the submitted work. Y Samodra reports leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), with the Benang Merah Research Center, Indonesia as co-founder; outside the submitted work. A E Schutte reports grants or contracts from National Health and Medical Research Council of Australia and Medical Research Future Fund; consulting fees from Sky Labs, Servier, and Medtronic; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier, Abbott, Sanofi, AstraZeneca, Medtronic, Omron, Aktiia; support for attending meetings and/or travel from Servier, and Medtronic; leadership or fiduciary role in other board, society, com-mittee or advo-cacy group (paid or unpaid), as Co-Chair, National Hypertension Taskforce of Australia, Secretary, Australian Cardiovascular Alliance, and Board Member, Hypertension Australia; all outside the submitted work. V Sharma reports other financial or non-financial support from DFSS (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, USA, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs, Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health]; payment of honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events as a member of the speaker’s bureau of Simply Speaking; support for attending meetings as a past steering committee member of OMERACT; participation on a data safety monitoring board or advisory board with the FDA Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid as a past steering committee member of the OMERACT (an international organization that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies), unpaid as a Co-Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and unpaid as an editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; stock of stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding Corp, and Charlotte’s Web Holdings, and previous stock options in Amarin, Viking, and Moderna Pharmaceuticals; outside the submitted work. R Tabares-Seisdedos reports grants or contracts from Valencian Regional Government’s Ministry of Education (PROMETEO/ CIPROM/2022/58 and the Spanish Ministry of Science, Innovation and Universities (PID2021-129099OB-I00); outside the submitted work. J H V Ticoalu reports Leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), with Benang Merah Research Center, Indonesia as co-founder, outside the submitted work. M V Titova reports support for their participation in the current manuscript from the Ministry of Science and Higher Education of the Russian Federation (themes no. 122042600086-7). D Trico reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Eli Lilly, and Novo Nordisk; support for attending meetings and/or travel from AstraZeneca; participation on a data safety monitoring board or advisory board from Amarin, Boehringer Ingelheim, and Novo Nordisk; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), with EASD Early Career Academy and EASD Committee on Clinical Affairs; receipt of equipment, materials, drugs, medical writing, gifts or other services from Abbott and PharmaNutra; all outside the submitted work. E Upadhyay reports patents issued, planned, or pending, for A system and method of reusable filters for anti-pollution mask, A system and method for electricity generation through crop stubble by using microbial fuel cells, A system for disposed personal protection equipment (PPE) into biofuel through pyrolysis and method, A novel herbal pharmaceutical aid for formulation of gel and method thereof , Herbal drug formulation for treating lung tissue degenerated by particulate matter exposure, and A method to transform cow dung into the wall paint by using natural materials and composition thereof; leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid), with the Executive Council Member, Indian Meteorological Society, Jaipur Chapter. (India) and Member Secretary- DSTPURSE Program; all outside the submitted work. P Willeit reports grants or contracts from Novartis Pharmaceuticals, outside the submitted work. M Zielińska reports other financial or non-financial in Alexion, AstraZeneca Rare Disease as an employee. E Zweck reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and support for travel and/or travel from Abiomed, outside the submitted work.